Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Using CHIP to encourage early intervention in disease

Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, explains the importance of early intervention in myeloproliferative neoplasms (MPNs), and further highlights the value of identifying clonal hematopoiesis of indeterminate potential (CHIP) and other mutations, and informing patients on the risks associated with these. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Aptose Biosciences – employment and equity
Gilead – data safety monitoring committees chair
Epizyme – data safety monitoring committee chair
BMS – ad hoc advisory board honoraria, research funding
Takeda – research funding